Special Session

Presidential Symposium II - EL04 - Treating the Primary Site is Necessary in Curing Metastatic Disease

10:15 AM - 11:45 AM
Location: Room W179

Session Type: Special Session
0.00 AMA PRA Category 1 Credits™

During this session the following key questions will be discussed and debated:

1. Is treatment of the primary a "no brainer" for attempted cure of metastatic disease?
2. Should the primary be treated in an ablative or non-ablative manner when treating patients with metastatic disease?

After two level setting presentations, participants will be divided into groups, each of which will be assigned to address one of the two questions above. Each group will be asked to define 3-5 "pro" and 3-5 "con" arguments for each question. Groups will be asked to work collaboratively in teams to address each of the topics. After group work is performed, each "pro" and "con" section will be presented to the group at large. As a final conclusion a vote will be taken on each of these questions to determine an answer based on the entire sessions voted agreement.


Daniel Gomez, MD

Memorial Sloan Kettering Cancer Center


Send Email for Daniel Gomez

David Raben, MD, FASTRO

University of Colorado Denver

David Raben, M.D. is currently faculty at the University of Colorado where he is a board-certified Professor of Radiation Oncology holding the Marsico Endowed Chair for HNC Research. He received a B.A. in Psychology from Duke University in 1985 and then completed his M.D. at Wake Forest University/Bowman Grey School of Medicine in 1990. After graduation, he did his internship at the University of Hawaii and residency in Radiation Oncology at the Johns Hopkins Hospital from 1991-1994, serving as a chief resident in 1994. He took his initial faculty position at the University of Alabama at Birmingham from 1994-1998 before joing the University of Colorado. Dr. Raben has developed expertise over the past 20 years in translational radiation oncology with a focus on delivery of precision drugs and exploration of molecular biomarkers that will enhance the effects of radiation therapy. He serves on the NRG HNC steering committee and translational committee focusing on NCI approved clinical trials devoted to HNC. Dr. Raben also serves on the SWOG GU Steering committee for prostate and bladder cancer. He currently serves as the Developmental Therapeutics co-Chair at the NRG with responsibilities to initiate and implement Phase I trials with radiation and novel drugs. From a research perspective, his focus has been on heavy smoker HNC patients who have high levels of DNA repair capabilities offering approaches that will inhibit DNA repair while studying which biomarkers might predict response. Additional work has focused on the use of TGFb inhibitors as both radioprotectors and to enhance anti-PDL1 inbibition in head and neck models. Recently accepted for publication was the first radiation trial with an anti-EGFR inhibitor and a PARP inhibitor in locally advanced HNC. Dr Raben was named as an ASCO daily News Associate Editor in 2018. He has authored over 150 publications.


Send Email for David Raben

William Hall, MD

Medical College of Wisconsin

I am a board certified radiation oncologist with a passion for research in gastrointestinal malignancies, and radiological sciences. Thus far, in the early portion of my career, I have devoted my efforts to understanding the integration of advanced imaging modalities, including MRI, into radiation treatment planning. Moreover, I have published several peer-reviewed articles devoted to the optimal use of radiation therapy for gastrointestinal malignancies and prostate cancer. Such articles have specifically related to radiation therapy technological advances, MRI incorporation into radiation planning, and the optimal radiation therapy dosing strategy. My future research goals are focused on developing and improving our ability to identify patients that may not require surgery for rectal cancer. In addition, I hope to develop MRI strategies that would use novel and unique MRI sequences to enable precise delineation of the most malignant portions of a tumor. My aspiration is to work closely with collaborators to refine our ability to accurately identify malignant tissue and direct intensification of local radiation therapy. I see the next decade of research to be an exciting and transformative time in the management of several different malignancies and I am looking forward to making whatever contributions I can.


Send Email for William Hall


Presidential Symposium II - EL04 - Treating the Primary Site is Necessary in Curing Metastatic Disease

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Presidential Symposium II - EL04 - Treating the Primary Site is Necessary in Curing Metastatic Disease